Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
VIGONVITA LIFE SCIENCES CO., LTD. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner and 1 distinct art unit, representing a focused point of contact within the patent office. For a company operating in the technical fields of biotechnology and pharmaceuticals, this concentration means that the immediate success of their patent prosecution rests on a singular interaction rather than a broad portfolio of diverse applications. The alignment of 1 examiner and 1 art unit suggests that the subject matter is specialized and has not yet branched into multiple technical classifications.
The specific examiner assigned to this case is BERRY, LAYLA D, who is also listed as the busiest examiner for the portfolio with 1 pending office action. Because there is only 1 pending action in total, this examiner handles the entirety of the company's current workload. This creates a scenario where the practitioner can focus resources on understanding the specific examination style and prior art preferences of BERRY, LAYLA D. The presence of only 1 distinct examiner and 1 distinct art unit simplifies the communication path but also focuses the success of the active filing on a single set of examiner expectations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287722 | NUCLEOSIDE COMPOUND AND APPLICATION THEREOF IN THE TREATMENT OF FELINE INFECTIOUS PERITONITIS | BERRY, LAYLA D | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287722 | NUCLEOSIDE COMPOUND AND APPLICATION THEREOF IN THE TREATMENT OF FELINE INFECTIOUS PERITONITIS | BERRY, LAYLA D | 1693 | §101§102 | Final Rejection | — | Pending | Oct 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVIGONVITA LIFE SCIENCES CO., LTD. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Layla D Berry has the most, with 1 of VIGONVITA LIFE SCIENCES CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
